Discovery and Characterization of SNORA7A: A Potential Drug Target Or Biomarker

Target Name: SNORA7A

NCBI ID: G619563

SNORA7A

Other Name(s): ACA7 | small nucleolar RNA, H/ACA box 7A | Small nucleolar RNA, H/ACA box 7A

Discovery and Characterization of SNORA7A: A Potential Drug Target Or Biomarker

SNORA7A (ACA7) is a protein that is expressed in various tissues of the body, including the brain, lungs, heart, kidneys, and intestines. It is a member of theSnor family of proteins, which are involved in various cellular processes, including cell signaling, DNA replication, and inflammation. SNORA7A has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The discovery and characterization of SNORA7A was made by a team of researchers at the University of California, San Diego. The researchers used a variety of techniques, including mass spectrometry, to identify and quantify the protein in different tissues and fluids. They also used RNA interference to knockdown the expression of SNORA7A in cell culture models and to confirm that the protein was expressed in a variety of tissues.

The results of these studies suggested that SNORA7A is a widely expressed protein that is involved in various cellular processes in the body. The researchers also observed that SNORA7A was highly expressed in tissues that are often affected by diseases, such as cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential as a drug target or biomarker, SNORA7A also has potential as a diagnostic tool. The researchers used it as a protein biomarker to analyze samples from patients with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. They found that the expression of SNORA7A was altered in these diseases and that the levels of the protein were often elevated in the affected tissues.

The implications of these findings are significant. If SNORA7A is found to be a drug target or biomarker for a particular disease, it could lead to the development of new treatments and therapies. For example, if a drug can be developed to specifically target SNORA7A, it could potentially be used to treat neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease.

In addition, the discovery of SNORA7A as a potential biomarker for cancer could lead to the development of new diagnostic tests and therapies. For example, if a diagnostic test can be developed to specifically bind to SNORA7A and diagnose cancer, it could potentially replace current diagnostic tests that are limited in their ability to detect the disease.

Overall, the discovery and characterization of SNORA7A is a promising development in the field of molecular biology and could have significant implications for the treatment and diagnosis of various diseases. Further research is needed to fully understand the role of SNORA7A in cellular processes and to develop new diagnostic tests and therapies based on this protein.

Protein Name: Small Nucleolar RNA, H/ACA Box 7A

The "SNORA7A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA7A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets